512529 Stoklara Genel Bakış Sequent Scientific Limited Avrupa, Asya ve uluslararası alanda veteriner sağlık hizmetleri alanında faaliyet göstermektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Sequent Scientific Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Sequent Scientific Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı ₹178.50 52 Haftanın En Yüksek Seviyesi ₹240.90 52 Haftanın En Düşük Seviyesi ₹91.85 Beta 0.81 1 Aylık Değişim -7.08% 3 Aylık Değişim 2.97% 1 Yıllık Değişim 51.08% 3 Yıllık Değişim 13.62% 5 Yıllık Değişim 149.83% Halka arzdan bu yana değişim 1,568.22%
Son Haberler & Güncellemeler
Sequent Scientific Limited Announces Executive Changes Dec 19
Second quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.34 loss in 2Q 2024) Nov 14
Sequent Scientific Limited to Report Q2, 2025 Results on Nov 13, 2024 Nov 07
Sequent Scientific Limited Announces Cessation of Kausalya Santhanam as Independent Director Oct 28 Sequent Scientific and Viyash Life Sciences Reportedly Explore Merger Worth INR 70,000 Million-INR 80,000 Million Sep 28
Sequent Scientific Limited (BSE:512529) agreed to acquire Viyash Life Sciences Private Limited for INR 38 billion. Sep 27
Daha fazla güncelleme görün
Sequent Scientific Limited Announces Executive Changes Dec 19
Second quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.34 loss in 2Q 2024) Nov 14
Sequent Scientific Limited to Report Q2, 2025 Results on Nov 13, 2024 Nov 07
Sequent Scientific Limited Announces Cessation of Kausalya Santhanam as Independent Director Oct 28 Sequent Scientific and Viyash Life Sciences Reportedly Explore Merger Worth INR 70,000 Million-INR 80,000 Million Sep 28
Sequent Scientific Limited (BSE:512529) agreed to acquire Viyash Life Sciences Private Limited for INR 38 billion. Sep 27
Sequent Scientific Limited, Annual General Meeting, Sep 17, 2024 Aug 27
Sequent Scientific Limited Receives WHO Prequalification Approval for Albendazole API Aug 21
New major risk - Financial position Aug 16
Sequent Scientific Limited to Report Q1, 2025 Results on Aug 14, 2024 Aug 09
New minor risk - Share price stability Jul 15
Full year 2024 earnings released: ₹1.44 loss per share (vs ₹4.88 loss in FY 2023) May 16
Sequent Scientific Limited to Report Q4, 2024 Results on May 15, 2024 May 10
Sequent Scientific Limited Announces Resignation of Sharat Pandurang Narasapur, Jt. Managing Director, from the Board of Directors, Member of the Corporate Social Responsibility Committee of the Board Effective on April 30, 2024 Apr 04
Third quarter 2024 earnings released: EPS: ₹0.33 (vs ₹0.36 loss in 3Q 2023) Feb 14
Sequent Scientific Limited Announces Executive Changes Feb 13
Sequent Scientific Limited to Report Q3, 2024 Results on Feb 13, 2024 Feb 07
Sequent Scientific Limited Announces Resignation of Krunal Shah as Company Secretary & Compliance Officer, Effective on February 15, 2024 Dec 06
Sequent Scientific Limited to Report Q2, 2024 Results on Nov 06, 2023 Oct 31
Sequent Scientific Limited Announces Patri Venkat Raghavendra Rao as Chief Financial Officer Oct 17
Sequent Scientific Limited, Annual General Meeting, Aug 30, 2023 Aug 09
Sequent Scientific Limited to Report Q1, 2024 Results on Aug 10, 2023 Aug 05 Sequent Scientific Limited Announces Discontinuation of Manufacturing Operations At Tarapur, Maharashtra Jul 15
Full year 2023 earnings released: ₹4.88 loss per share (vs ₹1.67 profit in FY 2022) May 24
Third quarter 2023 earnings released: ₹0.36 loss per share (vs ₹0.69 profit in 3Q 2022) Feb 15
Sequent Scientific Limited Announces Resignation of Rahul Mukim as Director Dec 08
Price target decreased to ₹149 Nov 16
High number of new and inexperienced directors Nov 16
Second quarter 2023 earnings released: ₹0.15 loss per share (vs ₹0.58 profit in 2Q 2022) Nov 09
Sequent Scientific Limited (BSE:512529) agreed to acquire Tineta Pharma Private Limited from group of shareholders for INR 2.18 billion. Nov 08 Sequent Scientific Limited to Report Q2, 2023 Results on Nov 14, 2022
Sequent Scientific Limited, Annual General Meeting, Sep 20, 2022 Aug 27
First quarter 2023 earnings released: ₹0.57 loss per share (vs ₹0.04 profit in 1Q 2022) Aug 10
Sequent Scientific Limited to Report Q1, 2023 Results on Aug 08, 2022 Aug 03
Investor sentiment improved over the past week Jul 20
Sequent Scientific Limited Appoints P V Raghavendra Rao as the Chief Financial Officer Jul 16
Investor sentiment deteriorated over the past week Jun 20
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 27
Investor sentiment improved over the past week May 23
Sequent Scientific Limited to Report Q4, 2022 Results on May 25, 2022 May 20
Price target decreased to ₹170 Apr 27
High number of new and inexperienced directors Apr 27
Sequent Scientific Limited Announces Resignation of Tushar Mistry Chief Financial Officer, Effective May 31, 2022 Apr 15 Sequent Scientific Limited Announces Resignation of Mr. Manish Gupta from the Position of CEO Sequent Scientific Limited Announces Appointment of Rajaram Narayanan as Managing Director
CEO, MD & Executive Director recently sold ₹73m worth of stock Apr 06
Investor sentiment improved over the past week Apr 04
CEO, MD & Executive Director recently sold ₹84m worth of stock Mar 28
CEO, MD & Executive Director recently sold ₹23m worth of stock Mar 06
Investor sentiment deteriorated over the past week Feb 24
CEO, MD & Executive Director recently sold ₹27m worth of stock Feb 23
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 13
Price target decreased to ₹197 Jan 25
Insider recently sold ₹5.7m worth of stock Jan 05
Investor sentiment deteriorated over the past week Nov 30
Insider recently bought ₹1.4m worth of stock Nov 13
Second quarter 2022 earnings released: EPS ₹0.58 (vs ₹0.86 in 2Q 2021) Nov 04
Second quarter 2022 earnings released: EPS ₹0.58 (vs ₹0.86 in 2Q 2021) Nov 04
Investor sentiment deteriorated over the past week Oct 22
Insider recently sold ₹17m worth of stock Sep 09
Insider recently sold ₹17m worth of stock Aug 27
Full year 2021 earnings released: EPS ₹3.87 (vs ₹2.87 in FY 2020) Jul 03
Investor sentiment improved over the past week Jun 30
Investor sentiment improved over the past week Apr 28
Insider recently sold ₹1.3m worth of stock Feb 21
Third quarter 2021 earnings released: EPS ₹1.54 (vs ₹0.83 in 3Q 2020) Feb 04
New 90-day high: ₹232 Feb 03
Sequent Scientific Limited to Report Q3, 2021 Results on Feb 03, 2021 Jan 26
Investor sentiment improved over the past week Jan 19
New 90-day high: ₹214 Jan 19
New 90-day high: ₹181 Jan 04
Chief Financial Officer recently sold ₹7.7m worth of stock Dec 22
Sequent Scientific Limited Appoints Fabian Kausche as an Additional (Non-Executive Non-Independent) Director Dec 16
Insider recently sold ₹8.7m worth of stock Dec 10
New 90-day high: ₹168 Dec 07
Sequent Scientific Limited Announces Launch of Inhouse Developed Halofusol® in EU Dec 03
Insider recently sold ₹79m worth of stock Nov 25
Insider recently sold ₹3.8m worth of stock Nov 14
Second quarter 2021 earnings released: EPS ₹0.86 Nov 08
Sequent Scientific Limited Appoints Gregory John Andrews as an Additional Director with Effect from November 6, 2020 Nov 07
Sequent Scientific Limited to Report Q2, 2021 Results on Nov 06, 2020 Nov 01
Insider recently sold ₹77m worth of stock Oct 03
New 90-day high: ₹159 Sep 28
Pronomz Ventures LLP completed the acquisition of 3.7% stake in Strides Pharma Science Limited (NSEI:STAR) from Sequent Scientific Limited (BSE:512529) Sep 26 Sequent Scientific Limited Announces Receipt of WHO - Geneva Approval for API Praziquantel (Anthelmintic) Under Pre-Qualification Program
CEO, MD & Executive Director recently sold ₹4.3m worth of stock Sep 13
New 90-day high - ₹146 Sep 11
Insider recently sold ₹38.8m worth of stock Aug 27
Sequent Scientific Limited (BSE:512529) agreed to acquire an additional unknown minority stake in Provet Veteriner Urunleri San. VeTic. A.S. Aug 13
Sequent Scientific Limited to Report Q1, 2021 Results on Jul 30, 2020 Jul 31 Hissedar Getirileri 512529 IN Pharmaceuticals IN Pazar 7D -5.9% 0.8% -4.2% 1Y 51.1% 39.7% 19.1%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 512529 geçen yıl % 39.7 oranında getiri sağlayan Indian Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: 512529 geçen yıl % 19.1 oranında getiri sağlayan Indian Piyasasını aştı.
Fiyat Oynaklığı Is 512529's price volatile compared to industry and market? 512529 volatility 512529 Average Weekly Movement 8.3% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
İstikrarlı Hisse Senedi Fiyatı: 512529 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: 512529 'nin haftalık oynaklığı ( 8% ) geçen yıl boyunca sabit kaldı, ancak hala Indian hisselerinin %75'inden yüksek.
Şirket Hakkında Kuruldu Çalışanlar CEO Web sitesi 1985 1,195 Rajaram Narayanan www.sequent.in
Sequent Scientific Limited, Avrupa, Asya ve uluslararası alanda veteriner sağlık hizmetleri sektöründe faaliyet göstermektedir. Şirket, endo ve ekto parazit öldürücüler dahil olmak üzere antelmintikler ve anti-protozoal, nutrasötikler, nonsteroid anti-enflamatuar ilaçlar, anti-enfektifler ve dermatoloji alanlarında hayvan sağlığı aktif farmasötik bileşenleri (API'ler) formülasyonları sağlar. Ayrıca API, farmasötik, kişisel bakım ve nutrasötik kuruluşlarını destekleyen analitik çözümler ve API'ler ve bitmiş ürünler için yöntem doğrulama, stabilite ve mikrobiyoloji sunmaktadır.
Daha fazla göster Sequent Scientific Limited Temel Bilgiler Özeti Sequent Scientific'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 512529 temel i̇stati̇sti̇kler Piyasa değeri ₹44.51b Kazançlar(TTM ) ₹164.81m Gelir(TTM ) ₹14.49b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 512529 gelir tablosu (TTM ) Gelir ₹14.49b Gelir Maliyeti ₹8.10b Brüt Kâr ₹6.39b Diğer Giderler ₹6.23b Kazançlar ₹164.81m
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/21 03:40 Gün Sonu Hisse Fiyatı 2024/12/20 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2024/03/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Sequent Scientific Limited 2 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Nikhil Shetty BP Wealth Management Private Limited null null IIFL Wealth Management Ltd.
Göster 0 daha fazla analist 
